NICE Approves Enhertu for 1,000 England Breast Cancer Patients After 2-Year Campaign
Updated
Updated · Positive.News · Sep 18
NICE Approves Enhertu for 1,000 England Breast Cancer Patients After 2-Year Campaign
3 articles · Updated · Positive.News · Sep 18
Summary
Enhertu is now available in England for patients with incurable HER2-low metastatic breast cancer, reversing NICE’s 2024 rejection after a two-year push by patients and charities.
The drug can extend life by an average of seven months, with some patients living up to three years longer, making the decision significant for about 1,000 women a year.
NICE had previously blocked Enhertu as too expensive even though Scotland and 26 EU countries already offered it through their health systems.
Breast Cancer Now welcomed the reversal and urged Wales and Northern Ireland to follow, framing the move as renewed hope for patients seeking more time with their families.